BERMES project seeks to develop a new cure for Malignant Mesothelioma

The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposure